"Eliminating the infection is certainly very useful because it prevents the disease from continuing - underlines Pani - but if the disease does not exist yet, that is, there is the infection but the degree of fibrosis in the liver is minimal or even zero, that patient can wait. Drugs will arrive that will cure in less time with fewer side effects and that will cost less".
Regarding the controversy over the very high cost of the drug, Pani underlined that “we are buying at the lowest price in Europe. We cannot reveal the details of the negotiating agreement because this would invalidate the agreement and therefore we would lose this huge advantage, it can be said that we have closed a contract, and it is public, a
And he also intervened on the cost of the drug Enrico Rossi, President of the Tuscany Region, according to which the price snatched from AIFA is still too high and prevents all the sick from being treated. Rossi also recalls that the Tuscany Region had launched a tender inviting pharmaceutical companies to submit an offer. For Pani, however, "the solution is to go to supranational, not regional tenders. If there has been a mistake in our negotiating skills, it hasn't been as a country - concludes Pani - but as a European continent. We have to negotiate in a multinational way against the multinationals”.
Related news: AIFA registers: the Agency provides information on treatment data with new drugs for the treatment of hepatitis C